Please try another search
© Reuters.
By Dhirendra Tripathi
Investing – Merck (NYSE:MRK) shares rose 1% Thursday ahead of the day’s listing of Organon (NYSE:OGN_w), its spun-off business that has a broad portfolio of medicines and products.
The spinoff is expected to net Merck incremental operating efficiencies of approximately $1.5 billion over three years, with approximately $500 million realized during 2021. In connection with the spinoff, Merck received approximately $9 billion of Organon.
The announcement of the spin-off is one of the several positive developments that have happened at the German company this month.
The completion of the spin-off follows three announcements on Tuesday, only one of which was made by Merck.
The first was the launch of VAXELIS, the only hexavalent (six-in-one) combination vaccine in the U.S. indicated for active immunization to help prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to haemophilus influenzae type b.
VAXELIS is approved for use as a 3-dose series in children 6 weeks through 4 years of age (prior to the 5th birthday).
The novel vaccine has been developed as part of a U.S.-based partnership between Merck and Sanofi Pasteur (NASDAQ:SNY).
In Tuesday’s second announcement, biotechnology company Immutep (NASDAQ:IMMP) announced it will collaborate with Merck in the safety trial of an immunotherapy treatment the Sydney, Australia-based company is developing for cancer.
The trial will be done in combination with another immunotherapy that Merck and GlaxoSmithKline (NYSE:GSK) are jointly developing.
Tuesday’s third disclosure involving Merck was California-based Sutro Biopharma (NASDAQ:STRO) saying it has received a milestone payment from Merck for patient enrollment to study next-generation cancer and autoimmune therapeutics.
By Rozanna Latiff KUALA LUMPUR (Reuters) - Malaysian prosecutors on Friday wrapped up their arguments against former premier Najib Razak's final bid to overturn a 12-year jail...
By Senad Karaahmetovic Applied Materials (NASDAQ:AMAT) reported FQ3 results that came in higher than what the market was expecting. The Adjusted EPS came in at $1.94 on revenue of...
(Reuters) - Foot Locker (NYSE:FL) Inc said on Friday it had appointed former Ulta Beauty (NASDAQ:ULTA) head Mary Dillon as its chief executive officer, effective Sept. 1....
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.